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INTRODUCTION 
 
Intracellular cholesterol homeostasis is a tightly regulated process aimed at balancing the flux of 
cholesterol entering and exiting the cell. Defects in cellular cholesterol metabolism have been 
linked  to  a  variety  of  diseases  ranging  from  atherosclerosis  to  Alzheimer’s  disease.  The  
pathogenesis of these diseases are, however, quite complex, and it has been challenging to 
pinpoint the exact cellular processes that lead to disease progression, although the relationship 
between circulating cholesterol levels and atherosclerosis has been well documented. In general, 
LDL particles in the circulation are clinically regarded as “bad cholesterol” since these particles 
get entrapped in the vascular wall, leading to atherosclerosis. Circulating HDL particles are 
conversely regarded as “good cholesterol” because of their ability to transport cholesterol from 
peripheral tissues to the liver for secretion as bile salts.   
 
During the progression of atherosclerosis, LDL cholesterol accumulates in the wall of arteries, 
especially in places with high shear stress. Once inside the vessel intima, the LDL particles 
undergo a series of chemical modifications either by enzymatic processes or through oxidation. 
The modified LDL particles are then engulfed by macrophages, resulting in macrophage foam 
cells. If the macrophage foam cells are not able to efflux the cholesterol back into the 
bloodstream, the excessive cholesterol ultimately leads to cell death, and the deposition of 
cellular debris within the atherosclerotic lesion. The cells ability to secrete cholesterol is mainly 
dependent on the ABCA1 transporter which transfers cholesterol to extracellular apoA-I 
particles, yielding nascent HDL particles. The nascent HDL particles are then further enriched 
with cholesterol by the ABCG1 transporter. The process of atherosclerotic plaque development is 
therefore to a large extent a cellular one, in which the capacity of the macrophages in handling 
the excessive cholesterol load determines the progression of lesion development. Hence it is of 
great importance to understand how cholesterol is transported within the cell. To achieve this we 
have utilized the autosomal recessive cholesterol transport disease Niemann-Pick type C (NPC), 
as a cellular model and tool to study the processes governing intracellular sterol transport. 
 
In the first part of the study we characterized the mutations in an NPC1 disease patient and 
studied the consequences of the individual mutations on the function of the NPC1 protein. A 
  10
major finding was that mutations in the NPC1 protein cause an upregulation of NPC2 protein 
gene transcription, lending further support to the theory that these two proteins might function in 
concert to facilitate cholesterol egress from the endosomal system. 
 
In the second part of the study we used NPC1 disease cells as a cellular model for cholesterol 
accumulation, in order to identify individual Rab GTPases involved in cholesterol efflux from the 
endosomal system. Using a combination of fluorescent microscopy and biochemical techniques 
we identified Rab8 as a key protein in facilitating the transport of endocytosed LDL cholesterol 
to extracellular acceptors. Knock-down of the Rab8 protein with RNAi resulted in intracellular 
cholesterol accumulation, while overexpression of Rab8 alleviated the cholesterol storage 
phenotype seen in NPC1 disease cells.  
 
In the third part of the study we studied the role of Rab8 in macrophage foam cell formation and 
cholesterol processing. We found that Rab8 is expressed in macrophage foam cells of 
atherosclerotic lesions. Overexpression of Rab8 in primary human macrophages induced 
ABCA1-mediated cholesterol efflux to apoA-I. Rab8 facilitated the efflux of cholesterol from 
macrophage foam cells by regulating ABCA1 protein levels at the cell surface, as well as 
facilitating cholesterol traffic to ABCA1 substrate pools.  
 
 
 REVIEW OF THE LITERATURE 
 
1. PATHOPHYSIOLOGY OF ATHEROSCLEROSIS 
 
1.1 Atherogenic lipoproteins and macrophage foam cell formation 
 
Although several proatherogenic factors have been identified, the level of circulating LDL 
particles stands out as the most important determinant of lesion development. Atherosclerotic 
plaques start out as fatty streaks in the intima of middle and large diameter arteries already at 
early adulthood. The process of plaque formation is complex but lesions usually form at places 
with high shear stress. LDL is deposited in the intimal matrix of the artery where it is modified to 
yield so called minimally modified LDL (mmLDL) and oxidized LDL (oxLDL) (Schwenke and 
Carew, 1989; Williams and Tabas, 1998). MmLDL can still be recognized by LDL receptors 
while oxLDL is no longer recognized (Navab et al., 1996). Instead, oxLDL is taken up by 
macrophages via different receptors, the most important of which are CD36 and scavenger 
receptor A1 (SR-A1). The lesional macrophages are derived from infiltrating monocytes that are 
attracted to the site by various chemotactic factors, which can be secreted by other cells in the 
lesion, or can be components of oxLDL, e.g. lyso-phosphatidylcholine (lyso-PtdCho) (Hansson 
and Libby, 2006; Quinn et al., 1987).      
 
Blood-borne monocytes infiltrate the arterial intima and differentiate into macrophages, which 
take up modified LDL particles. This is initially thought to serve as an atheroprotective function. 
The internalized cholesterol is stored as cholesterol esters in cytoplasmic lipid droplets. 
Macrophages are, however, not capable of downregulating the scavenger receptors on the plasma 
membrane, which leads to continued scavenging of lipoprotein particles and expanding 
intracellular cholesterol stores, giving a foamy appearance of the cytoplasm. The foam cells are 
not able to efflux cholesterol at the same rate as uptake, leading to cell death, and the deposition 
of cellular debris in the arterial intima (Figure 1).  
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Figure 1 Macrophage foam cells in atherosclerotic lesion development. Circulating LDL 
particles accumulate in the intima of arteries, and undergo chemical modification, resulting in 
oxidized LDL (oxLDL). Blood-borne monocytes infiltrate the area and differentiate into 
macrophages that scavenge the oxLDL particles. Macrophage foam cells undergo apoptosis 
which results in a necrotic core, leading to further lesion development. Modified from (Glass and 
Witztum, 2001). 
 
1.2 Macrophage reverse cholesterol transport 
 
Reverse cholesterol transport (RCT) is the process of net cholesterol flux from peripheral tissues 
to the liver (Cuchel and Rader, 2006). In terms of atherosclerosis, the process of macrophage 
RCT warrants the most attention, although conceivably RCT might also take place from other 
cells in the atherosclerotic lesion. In terms of macrophage RCT, the combined role of the ATP-
binding cassette transporters ABCA1 and ABCG1 seem to be the most important. ABCA1 was 
found to be mutated in Tangier disease (Bodzioch et al., 1999; Brooks-Wilson et al., 1999; Rust 
et al., 1999) Although SR-B1 has also been implicated in cholesterol efflux in vitro it is not 
involved in macrophage RCT in the mouse (Wang et al., 2007).   
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1.2.1 ABCA1 mediated lipid efflux 
 
The primary function of ABCA1 is thought to be the lipidation of apolipoprotein A-I (apoA-I) at 
the plasma membrane (Denis et al., 2008), although intracellular compartments may also be 
involved (Cavelier et al., 2006; Hassan et al., 2008; Neufeld et al., 2004). However, the 
contribution of intracellular apoA-I to total HDL production has been estimated to be only ~1.4% 
of total HDL production (Denis et al., 2008). The precise mechanism of apoA-I lipidation is not 
known. It has been shown in numerous studies that apoA-I interacts directly with ABCA1 
(Chroni et al., 2004; Vedhachalam et al., 2004) and that the binding is essential for ABCA1 
mediated lipid transfer to ABCA1 (Fitzgerald et al., 2002). However, there seems to be two 
separate binding sites for apoA-I on the plasma membrane, a low- capacity binding site, thought 
to represent direct binding to ABCA1, and a high-capacity binding site to membrane domains 
generated through ABCA1 action (Hassan et al., 2007; Vedhachalam et al., 2007). The binding of 
apoA-I to ABCA1 is relatively unspecific and apparently involves amphiphatic alpha-helices in 
apoA-I (Fitzgerald et al., 2002; Vedhachalam et al., 2007). Accordingly, N- and C-terminal 
domain mutants of apoA-I bind equally well to ABCA1. In contrast, insertion of apoA-I into the 
plasma membrane domains requires intact hydrophobic C-terminal domain alpha-helices (Gillotte 
et al., 1999; Saito et al., 2003; Saito et al., 2004). The lipidation process might involve the 
transfer of phospholipids to apoA-I, generating nascent HDL particles, a process which is 
defective in Tangier disease patients (von Eckardstein et al., 1998). ABCA1 might function by 
flipping of phospholipid species from the inner to the outer leaflet (Alder-Baerens et al., 2005), 
resulting in membrane bending and increased curvature, facilitating the binding and subsequent 
lipidation of lipid poor apoA-I at the plasma membrane (Vedhachalam et al., 2007). 
 
Binding of apoA-I to ABCA1 might initiate signaling responses via the Janus kinase 2, 
stabilizing the protein on the cell surface (Tang et al., 2006; Tang et al., 2004). ABCA1 and 
CDC42 are in close proximity of each other at the plasma membrane and Golgi compartment, 
and these proteins co-immunoprecipitate (Tsukamoto et al., 2001). It was subsequently shown 
that binding of apoA-I to ABCA1 also initiates signaling via CDC42 and phosphorylation of 
PAK-1 and p54JNK, leading to actin polymerization (Nofer et al., 2006). There is evidence that 
apoA-I interacts directly with ABCA1 since these proteins cross-link, indicating that they are in 
close proximity (<7 Å) of each other (Chroni et al., 2004; Denis et al., 2004; Fitzgerald et al., 
MATTS LINDER 
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2004; Wang et al., 2000). Additionally, binding of apoA-I enhances the interaction between 
ABCA1 and CDC42 (Nofer et al., 2006) 
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2. INTRACELLULAR CHOLESTEROL TRAFFICKING AND HOMEOSTASIS 
 
2.1 Uptake and processing of LDL cholesterol in the endosomal system 
 
Regulation of cellular cholesterol homeostasis is mainly achieved through balancing the amount 
of cholesterol uptake, synthesis and efflux. Circulaing LDL particles containing cholesterol bind 
to the LDL receptor at the cell surface. The LDL receptor complex is then internalized through 
clathrin-coated pits. Once endocytosed, the LDL particles dissociate from the LDL receptor 
which then recycles back to the cell surface (Matter et al., 1993). Cholesteryl esters in the LDL 
particle are then hydrolyzed by lysosomal acid lipase (LAL) to yield free (unesterified) 
cholesterol. Most of the cholesterol in the endocytic compartments is present in multivesicular 
endosomes (multivesicular bodies, MVB) and recycling endosomes, ~60% and ~20% 
respectively (Möbius et al., 2003). The internal membranes of MVBs contain the bulk of 
cholesterol and are enriched in the endosome specific phospholipid LBPA/BMP 
(lysobisphosphatidic acid / bismonoacyl-glycerophosphate) (Kobayashi et al., 1999). The free 
cholesterol exits the endosomal compartments in a process that is dependent on the NPC1 and 
NPC2 proteins. After exiting the endosomes, cholesterol is mainly distributed to the plasma 
membrane and Golgi apparatus by yet unidentified pathways, before finally reaching the ER. The 
ER is usually relatively cholesterol poor and cholesterol entering the ER is rapidly converted to 
cholesteryl esters by acyl-coenzyme A: cholesterol acyltransferase (ACAT), for storage in lipid 
droplets (Figure 2). 
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Figure 2. Cholesterol uptake and compartmentalization. LDL particles bind to the LDL-receptor 
at the plasma membrane, and are endocytosed through clathrin-coated pits. The LDL particle 
then dissociates from the LDLr which is recycled back to the plasma membrane. The cholesterol 
esters derived from the LDL particle is hydrolyzed in the endosomes to yield free cholesterol. The 
free cholesterol is transported out of the endosomal compartments to the plasma membrane and 
TGN before reaching the ER (dotted arrows). In the ER, the cholesterol is re-esterified by ACAT, 
and stored in lipid droplets.  (LDLr, LDL receptor; EE, early endosome; RE, recycling 
endosome; MVB, multi vesicular body; LE, late endome; LY, lysosome; ER, endoplasmic 
reticulum; LD, lipid droplet; TGN trans-Golgi network; N, nucleus )  
 
 
2.2 Regulation of cholesterol biosynthesis in the ER 
  
The ER is the main orchestrator of cellular cholesterol distribution and amount. However, the ER 
is a relatively cholesterol poor organelle with a cholesterol content of only 1% of total cellular 
cholesterol (Lange, 1991). The two main proteins mediating cholesterol regulation in the ER are 
REVIEW OF THE LITERATURE 
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HMG-CoA reductase (HMGR) and the Sterol response element binding protein (SREBP) 
Cleavage Activating Protein (SCAP), which forms a complex with SREBP in the ER (Goldstein 
et al., 2006). HMGR is the rate-limiting protein in de novo cholesterol biosynthesis, while SCAP 
regulates SREBP processing. Both proteins are regulated by sterol binding to the sterol-sensing 
domain (SSD) and the ER resident Insig proteins (Insig1 and Insig2). Rising cholesterol levels in 
the ER induces regulatory mechanisms at both transcriptional and posttranscriptional levels. 
Cholesterol binds directly to the SSD of SCAP, causing a conformational change in the SSD. 
This causes SCAP to bind to Insig proteins, leading to retention of the SCAP/SREBP complex in 
the ER, thus shutting down SREBP dependent gene transcription (Yang et al., 2002). HMGR is 
also regulated by sterols, but the outcome of Insig binding is entirely different. Binding of 
HMGR to Insigs leads to ubiquitinylation and subsequent degradation of HMGR in the 
proteasome, thus reducing de-novo cholesterol synthesis (Espenshade and Hughes, 2007; Sever 
et al., 2003).    
 
2.3 Transcriptional regulation of cholesterol levels 
 
There are two main transcriptional regulatory systems in the cell which work antagonistically to 
balance the intake, de novo synthesis and efflux of cholesterol, namely the sterol regulatory 
element  proteins  (SREBPs)  and  liver  X  receptors  (LXRs).  As  described  above,  the  SREBP  
system  is  regulated  by  ER  sterol  levels  through  the  SCAP  protein.  The  role  of  SCAP  is  to  
regulate the trafficking of SREBP to the Golgi. Upon cholesterol depletion in the ER, SREBP 
traffics to the Golgi where it is activated through a proteolytic process by the site1 (S1P) and 
site2 (S2P) proteases. The active transcription factor travels to the nucleus where it activates the 
transcription of gene products which increase intracellular cholesterol levels, e.g. HMGR and the 
LDL receptor (Goldstein et al., 2006). Conversely, activation of LXRs is mediated by oxysterols 
leading to the transcription of gene products that facilitate cholesterol efflux from the cell, e.g.  
the ABCA1 transporter (Tontonoz and Mangelsdorf, 2003).  
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3. NIEMANN-PICK TYPE C DISEASE 
 
3.1 Disease pathophysiology 
 
Niemann-Pick type C disease is a severe lysosomal cholesterol-sphingolipid storage disorder. 
The progress of the disease is varying with onset of symptoms ranging from early infancy to 
adulthood. Typically, the disease presents with neurological regression and peripheral 
manifestations due to massive cholesterol accumulation in the liver and spleen. Clinically the 
patients present with hepatosplenomegaly, ataxia, dystonia, seizures, supranuclear gaze palsy, 
and progressive dementia. Early-onset NPC disease is usually more severe and involves 
peripheral tissues with hepatosplenomegaly often observed. In the brain, there is degeneration of 
the brain stem and Purkinje neurons of the cerebellum (Walkley and Suzuki, 2004). Why only 
parts of the brain and specific subsets of neurons are affected is not understood, but the process is 
likely to involve both apoptosis and autophagy (Ko et al., 2005; Pacheco et al., 2007). A number 
of biochemical defects have been described, but the traditional hallmark of the disease is 
cholesterol accumulation in lysosomes combined with decreased esterification of cholesterol in 
the endoplasmic reticulum (ER) (Blanchette-Mackie et al., 1988). NPC has therefore historically 
been regarded as a cholesterol transport disorder. This is in contrast to Niemann-Pick types A and 
B, which are caused by acid sphingomyelinase deficiency. Interestingly, there is concomitant 
cholesterol accumulation in Niemann-Pick type A and B cells, and the depletion of cholesterol 
from these cells restores trafficking of fluorescently tagged lactosyl ceramide (BODIPY-LacCer) 
(Puri et al., 1999). These results emphasize the interdependence of cholesterol and sphingolipids 
in lysosomal storage disorders. Accordingly, in NPC disease there is a concomitant sphingolipid 
accumulation and decreased sphingomyelinase activity (Liscum and Klansek, 1998; Lloyd-Evans 
et al., 2008). The pathophysiology of NPC disease is however quite complex and it is has been 
challenging to pinpoint the precise pathological mechanism. Nevertheless it is likely that the 
disease phenotype is the combined result of aberrant cholesterol and sphingolipid metabolism. 
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Figure 3. Primary human fibroblasts from control and NPC1 patients. Cells are stained with 
filipin which visualizes free cholesterol (blue). NPC1 cells accumulate large amounts of 
cholesterol perinuclearly. 
 
One of the main cellular perturbations is a defect in the regulatory responses to cholesterol 
loading via the LDL pathway. Normally, cholesterol containing LDL particles taken up via the 
LDL-receptor, where after the cholesterol exits the endosomal system and is transported to the 
plasma membrane and to the ER, possibly via the trans-Golgi network (TGN). Superfluous 
cholesterol is then re-esterified by the ER resident protein acyl-CoA acyltransferase (ACAT) for 
storage in lipid droplets (Chang et al., 2001). In NPC disease cholesterol is trapped in aberrant 
endosomes and fails to reach the ER (Blanchette-Mackie et al., 1988; Pentchev et al., 1985) 
(Figure 3). This results in a relative cholesterol deficit in the ER, which is the primary sterol-
sensing organelle in the cell. As a result, there is a misregulation of the two major cholesterol 
homeostasis regulatory machineries i.e. the SREBP and LXR pathways. Thus, de novo 
cholesterol synthesis is not down-regulated, but rather increased (Liscum and Faust, 1987). Also 
the cholesterol efflux pathways are not up-regulated appropriately, and the LDL-receptor fails to 
down-regulate. The failure of down-regulation of the SREBP pathway can easily be attributed to 
the relative lack of cholesterol in the ER. Concomitantly, there is defective generation of 
oxysterols, the key activators of the LXR pathway (Frolov et al., 2003).        
 
 
 
Control NPC1 
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3.2 The NPC1 and NPC2 proteins 
 
Niemann-Pick disease type C is comprised of two separate genetic complementation groups with 
mutations in either of the NPC1 or NPC2 genes. Roughly 95% of disease cases are caused by 
mutations in the NPC1 gene whilst the remaining cases are accounted for by mutations in the 
NPC2 gene (Carstea et al., 1997; Naureckiene et al., 2000). The precise function of the two NPC 
proteins has not been established. However, lack of either protein leads to a nearly identical 
cellular phenotype, indicating that these proteins must perform similar functions in sterol egress 
from the endosomal system. Also, the NPC2/NPC1 double knockout mouse model displays an 
identical phenotype to that of NPC2 and NPC1 knockout models alone (Sleat et al., 2004). NPC2 
is a cholesterol binding protein present in lysosomes. NPC1 has been suggested to function as a 
transmembrane fatty acid transporter (Davies et al., 2000a), and more recently, as a sphingosine 
transporter (Lloyd-Evans et al., 2008). The conclusive evidence for a specific transport function 
for either of the proteins is however still lacking.   
 
3.2.1 Structural features and sterol binding of NPC1 
 
The gene mutated in the major complementation group was identified in 1997 through a 
positional cloning strategy. The gene product, named NPC1, was found to be a large, 1278 amino 
acid polytopic membrane protein with 13 transmembrane spans (Carstea et al., 1997) (Figure 4). 
A number of interesting domains have been identified in the protein, including a putative sterol-
sensing domain (SSD) comprising of transmembrane loops three through seven (Davies and 
Ioannou, 2000). This domain was originally identified in the SCAP (sterol regulatory element 
binding protein (SREBP) cleavage activating protein) and hydroxymethylglutaryl (HMG)-CoA 
reductase proteins (HMGR) (Osborne and Rosenfeld, 1998). Other proteins containing a SSD 
include the Hedgehog morphogen receptor Patched and 7-Dehydrocholesterol reductase 
(7DHCR) (Kuwabara and Labouesse, 2002), as well as Niemann-Pick type C 1 Like 1 (NPC1L1) 
(Davies et al., 2000b). The function of the SSD has most extensively been studied in SCAP and 
HMGR. The SSD is required for cholesterol dependent retention of SCAP in the ER, as well as 
lanosterol-induced ubiquitinylation and degradation of HMGR (Nohturfft et al., 1999; Song et al., 
2005). The evidence regarding a specific sterol-sensing function of the SSD in the NPC1 protein 
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is still inconclusive. NPC1 is capable of binding to a photoactivatable cholesterol analog, 
azocholestanol, while mutations in the SSD (P691S, Y634C) abolish this binding (Ohgami et al., 
2004). In vitro [3H]-cholesterol binding to the purified SSD of SCAP has also been established, 
but this was not inhibited by the corresponding Y298C mutation in SCAP (Radhakrishnan et al., 
2004). However this mutation in SCAP has previously been shown to inhibit the binding of 
SCAP to Insig proteins involved in 25-hydroxycholesterol sensing in the ER (Radhakrishnan et 
al., 2007; Yang et al., 2002). Also, mutations in NPC1, corresponding to gain of function 
mutations in SCAP, resulted in increased cholesterol trafficking in the cell (Millard et al., 2005). 
However, in a later study the sterol binding capacity of the NPC1 protein was limited to the N-
terminal domain (“NPC domain”) of purified NPC1 (Infante et al., 2008a). Mutations in the SSD 
are none the less clinically significant, and mutations in the SSD abolish the cholesterol transport 
function  of  NPC1  (Watari  et  al.,  1999b).   A  critical  role  for  the  N-terminal  domain  in  NPC1  
function has also previously been shown, as well as for the C-terminal LLNF lysosome-targeting 
motif (Watari et al., 1999b). Deletion of the C-terminal dileucine motif resulted in the retention 
of the NPC1 protein in the ER. Site directed mutagenesis of cysteins (C63S, C74S/C75S and 
C97S) resulted in non-functional NPC1 protein that localized to the surface of lysosomes (Watari 
et al., 1999a). 
 
 
 
 
 
 
Figure 4. Schematic representation of the NPC1 protein, The SSD is shown in red. Adapted from 
(Davies and Ioannou, 2000). 
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3.2.2 Subcellular localization and trafficking of NPC1  
 
The NPC1 and NPC2 proteins are thought to reside mainly in late endocytic compartments. The 
proteins show little co-localization, indicating that they are present in different subsets of 
endosomes. NPC1 colocalizes with the late endosomal/lysosomal marker Lamp2, but not with 
endocytosed LDL derived cholesterol or the mannose-6- phosphate receptor (MPR) (Neufeld et 
al., 1999). NPC1 has also been shown to colocalize with LBPA, Rab7, and Rab9 (Higgins et al., 
1999; Puri et al., 1999; Zhang et al., 2001b). Drugs that induce lysosomal cholesterol 
accumulation e.g. progesterone and U18666A redistributes NPC1 to cholesterol laden lysosomes 
(Neufeld et al., 1999). In normal cells NPC1 is thought to only transiently localize to cholesterol 
enriched organelles (Higgins et al., 1999; Kobayashi et al., 1999; Neufeld et al., 1999; Patel et al., 
1999; Watari et al., 1999a; Zhang et al., 2001b). Also the GM2 ganglioside localizes exclusively 
with NPC1, but not with endocytosed cholesterol (Osborne and Rosenfeld, 1998). 
 
Live cell microscopy using GFP-tagged NPC1 protein has revealed that NPC1 containing 
endosomes are highly mobile. NPC1 function seems to be dually required for both lipid sorting 
and tubular late endocytic trafficking (Ko et al., 2001). Also the motility of NPC1 containing 
endosomes is modulated by the lipid composition of the membranes, and is inhibited by 
cholesterol accumulation (Lebrand et al., 2002; Zhang et al., 2001a). NPC1-GFP containing 
organelles undergo tubulation and fission with both anterograde and retrograde migrations along 
microtubules.  This  movement  also  requires  an  intact  SSD  (Zhang  et  al.,  2001a).  Newly  
synthesized NPC1-GFP was also seen by live cell microscopy to be transported from the ER via 
the Golgi to late endosomes (Zhang et al., 2001a). NPC1 is ubiquitinylated upon cholesterol 
depletion which might influence the trafficking of NPC1 within different subsets of endosomes 
(Ohsaki et al., 2006).  
   
3.2.3 Structural features and lipid binding of NPC2 
 
The NPC2 gene product is a 151 amino-acid soluble lysosomal protein containing a 19 amino 
acid signal peptide which is cleaved off to generate the active 132 amino-acid protein. 
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Intracellular localization studies have shown that the protein resides both in Lamp1 positive and 
Lamp1 negative endosomes, as well as the Golgi apparatus. The NPC2 protein is glycosylated 
and contains a mannose-6-phosphate (M6P) post-translational modification conferring lysosomal 
targeting through binding to the mannose-6-phosphate receptor (MPR). The NPC2 protein was 
originally characterized as a cholesterol binding protein found in epididymal fluid named HE1 
(human epididymis protein 1) (Okamura et al., 1999). As a result of a screening for M6P 
containing proteins HE1 was found to localize to lysosomes. This allowed the identification of 
HE1 as the second protein in NPC disease, and the HE1 protein was renamed NPC2 
(Naureckiene et al., 2000).  
 
Structural analysis of the bovine NPC2 protein and site-directed mutagenesis strategies have 
shown the mechanism of cholesterol binding and identified functional domains in the protein. 
The bovine orthologue of NPC2, EPV20 had previously been purified from bovine milk (Larsen 
et al., 1997). The structure of the bovine homolog bNPC2 was elucidated by x-ray 
crystallography, revealing an Ig-like ?-sandwich fold consisting of seven ?-strands arranged in 
two ?-sheets (Friedland et al., 2003). Between the ?-sheets, three small cavities are formed with a 
total volume of 158 Å3. The volume of a cholesterol molecule is 741 Å3, indicating that the ?-
sandwich needs to expand in order to accommodate the cholesterol molecule. The structure of 
NPC2 bound to cholesterol-3-O-sulfate  also  supports  this  model  (Xu  et  al.,  2007).  X-ray  
crystallography of NPC2 bound to cholesterol sulfate indicates that the sterol is inserted into the 
cholesterol binding pocket with the iso-octyl side chain inside the pocket, and the sulfate group at 
position 3 of the A ring protruding from the entrance (Xu et al., 2007). Such an orientation would 
explain why NPC2 has low affinity for oxysterols (Infante et al., 2008a). A mutational screen 
based on evolutionally conserved residues highlights the importance of the cholesterol-binding 
cavity (Ko et al., 2003) (Figure 5).  
 
MATTS LINDER 
 24
 
Figure 5. Structure of the NPC2 sterol binding pocket. (A) Stereo view of the proposed sterol 
binding cavity. Sidechains of residues lining the cavity are shown in stick representation. Side 
chains required for cholesterol binding (Ko et al., 2003) are shown in red. (B) Space filling 
model of cholesterol (geeen) docked in the proposed sterol-binding site. Reprinted from 
(Friedland et al., 2003) with the permission of the publisher. Copyright (2003) National Academy 
of Sciences, U.S.A.  
 
 
The current evidence strongly favors a direct cholesterol shuttling model for NPC2 function.  
Several studies have now established that NPC2 binds cholesterol (Friedland et al., 2003; Infante 
et al., 2008a; Ko et al., 2003; Liou et al., 2006). NPC2 is able to extract and insert cholesterol 
from membranes in vitro (Cheruku et al., 2006) as well as shuttle cholesterol between liposomal 
vesicles (Babalola et al., 2007). NPC2 can also transfer cholesterol between the N-terminal 
domain of NPC1 and liposomes in vitro (Infante et al., 2008b). NPC2 is also involved in Thymal 
T cell selection by loading the MHC class I-like protein CD1d with the selecting 
glycosphingolipid isoglobotrihexosylceramide (iGb3) in NKT cells (Schrantz et al., 2007). 
Whereas the in vitro loading of iGb3 to CD1d required dimerization of NPC2, the transfer was 
not affected by cholesterol binding.  
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3.2.4 Subcellular localization and trafficking of NPC2 
 
The NPC2 protein resides mainly in the lumen of late endosomes/lysosomes. The intracellular 
trafficking of NPC2 is governed by the mannose 6-phosphate receptor (MPR) owing to the 
posttranslational addition of a mannose 6-phosphate moiety to the protein (Naureckiene et al., 
2000). The mannose 6-phosphate moiety is recognized by the MPR, which enables trafficking 
between the Golgi apparatus and lysosomes as well as uptake from the PM. Depletion of the two 
MPRs, MPR300 (cation-independent) and MPR46 (cation-dependent), in fibroblasts increases 
the secretion of NPC2 from cells (Willenborg et al., 2005). NPC2 is abundantly present in 
epididymal fluid and milk (Kirchhoff et al., 1996; Larsen et al., 1997), and can be secreted from 
cells in the cholesterol bound form (Ko et al., 2003; Okamura et al., 1999). NPC2 is also secreted 
from cultured glia cells, but does not associate with the major secretory sterol containing 
lipoprotein particles. Also, overexpression of NPC2 in glia cells does not enhance sterol secretion 
(Mutka et al., 2004). Secreted NPC2 can be re-endocytosed and is biologically active. Incubation 
of NPC2 cells with medium preconditioned by incubation with WT cells complements the 
cholesterol storage phenotype, but the complementation is inhibited by mannose-6 phosphate, 
indicating that endocytosis by MPR is required (Naureckiene et al., 2000). However 
overexpression of NPC2 mutants that are not properly secreted still complement the individual 
transfected cells, indicating that secretion is not an absolute necessity (Ko et al., 2003).  
 
NPC2 is glycosylated, appearing as two individual bands of 21 to 25 kDa in WB of human 
fibroblast samples. After removal of N-linked glycans with PNGaseF (protein:N-glycosidase F) 
the protein migrates at 18 kDa (Mutka et al., 2004). A mutational screen of the possible 
asparagine linked (Asn, N) glycosylation sites revealed that only two of the sites, N58 and N135, 
are utilized. The study also showed that glycosylation of Asn 58 is required for proper lysosomal 
targeting of NPC2 (Chikh et al., 2004).   
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4. RAB GTPases IN MEMBRANE AND CHOLESTEROL TRAFFICKING 
 
4.1 Rab GTPase function 
 
Rab proteins are small GTPases belonging to the Ras superfamily of GTPases (Wennerberg et al., 
2005). Rab proteins function as molecular switches, regulating events such as vesicle trafficking, 
motility, docking and fusion (Pfeffer, 2001; Zerial and McBride, 2001). Rab proteins cycle 
between the cytosol and target membranes in an active GTP-bound state and an inactive GDP-
bound state. The switching to the active state is mediated by guanine nucleotide exchange factors 
(GEFs), which mediate binding of GTP to the Rab protein. Inactivation is mediated by GTPase-
activating proteins (GAPs) which catalyze the intrinsic GTPase activity of the Rab protein, 
resulting in hydrolysis of the bound GTP to GDP (Pfeffer, 2001; Segev, 2001).  In the active GTP 
bound state, Rab proteins insert into the target membrane by virtue of a prenylation motif located 
in the C-terminal of the protein. Prenylation of Rab proteins is facilitated by Rab escort protein 
(REP) which presents newly synthesized Rab protein to Rab geranylgeranyl transferase 
(GGTase) (Andres et al., 1993). In the ‘soluble’ state Rab proteins are bound and sequestered in 
the cytosol by GDI (guanosine nucleotide dissociation inhibitor) (Figure 6). Human cells express 
two isoforms, GDI? which is enriched in the brain and the ubiquitously expressed GDI? (Alory 
and Balch, 2001). The binding of Rab proteins to GDI is strongly dependent on prenylation as 
well as the presence of GDP in the nucleotide binding site. Upon GDP- or GTP binding the Rab 
proteins change conformation in the highly conserved ‘switch region’, which is recognized by 
GDI. GDI can also extract Rab proteins from membranes (Sasaki et al., 1990; Ullrich et al., 
1993).  
 
The targeting of Rab proteins to specific membranes is thought to be mediated by the C-terminal 
‘hypervariable domains’ which are the most divergent amino acid stretches between different 
Rab proteins (Chavrier et al., 1991). The association of the Rab protein to GDI is probably 
modulated by the length of the hypervariable domain with affinities of 20-500nM Kd being 
reported (Schalk et al., 1996; Shapiro and Pfeffer, 1995). The deposition of Rab proteins into the 
target membrane is facilitated by GDI-displacement factors (GDF).  
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Figure 6. The Rab cycle. Rab GTPases are activated by guanine nucleotide exchange factors 
(GEFs). The Rab proteins then bind to effector proteins which can for instance be molecular 
motors. After fulfilling its task, the Rab protein is deactivated by GTPase activating proteins 
(GAPs), and removed from the membranes by guanine nucleotide dissociation inhibitor (GDI). 
Another round of action is initiated by GDI displacement factor (GDF) which facilitates the 
deposition of Rab proteins into the target membrane. 
 
4.2 Rab proteins in intracellular sterol trafficking 
 
Cholesterol efflux from the endosomal compartments seems to be mediated, at least in part, by 
Rab protein directed membrane trafficking. It was initially shown that inhibition of Rab protein 
function by microinjection of Rab-GDI inhibits cholesterol removal from endocytic 
compartments (Höltta-Vuori et al., 2000). So far, the individual Rab proteins that have been 
implicated in intracellular cholesterol trafficking localize to the endocytic compartments of the 
cell (Table 1). Choudhury and colleagues showed that overxpression of dominant negative Rab7 
or Rab9 inhibited the Golgi targeting of sphingolipids, and that overexpression of wild-type Rab7 
or Rab9 reduced the cholesterol accumulation in NPC1 fibroblasts (Choudhury et al., 2002). 
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Rab9 was subsequently shown to increase cholesterol efflux in two separate studies (Narita et al., 
2005) (Walter et al., 2003). In a recent study, the life span of Rab9 / NPC1-/- transgenic mice was 
also found to be increased by ~ 22 % as compared to NPC1-/- mice (Kaptzan et al., 2009). The 
dominant negative form of Rab4 also perturbs cholesterol recycling (Choudhury et al., 2004). 
Overexpression of Rab11 affects endosomal cholesterol trafficking, resulting in the accumulation 
of free cholesterol in recycling endosomes (Höltta-Vuori et al., 2002).  
 
Table 1. Localization and function of Rab proteins which have been shown to affect cholesterol 
transport in the endocytic compartments. 
Rab Localization Function Reference 
Rab4 Early and recycling 
endosomes 
Rapid endosomal recycling (van der Sluijs et al., 1992) 
Rab7 Late endosomes, 
lysosomes 
Early to late endosomal transport, 
Lysosome biogenesis 
(Press et al., 1998)     (Bucci 
et al., 2000) 
Rab9 Late endosomes,  
trans Golgi network 
Late endosome to Golgi transport (Lombardi et al., 1993) 
Rab11 Recycling endosomes Recycling through the endocytic 
recycling compartment (ERC) 
(Ullrich et al., 1996) (Ren et 
al., 1998) 
 
    
4.3 The Rab8 GTPase 
 
 
Two isoforms, Rab8A (referred to here as Rab8) and Rab8b have been identified in humans. 
Rab8 is ubiquitously expressed in tissues while Rab8b is predominantly expressed in the spleen, 
testis and brain (Armstrong et al., 1996). There is an 83% sequence identity between Rab8A and 
Rab8b, with the highest degree of divergence within the C-terminal hypervariable domain (Figure 
7) (Armstrong et al., 1996). Rab8 differs from other Rab proteins in that it is geranylgeranylated 
at a single site as opposed to the usual double geranylgeranylation. This is due to the presence of 
a CaaL motif instead of the usual CC or CXC motifs (Casey and Seabra, 1996; Wilson et al., 
1998). 
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Figure 7. Bar representation of Rab8A and Rab8b. Guanine base binding sites are indicated in 
black (aa 33; aa 119-125; aa 147-154). The hypervariable domain (aa 154-207) is indicated in 
yellow. The C-terminal prenylation motif CVLL is composed of aa 204-207. 
 
Rab8 affects cell shape, inducing cellular protrusions when overexpressed (Nachury et al., 2007) 
(Armstrong et al., 1996; Peränen et al., 1996). In two separate studies Rab8 was found to regulate 
primary cilium formation (Nachury et al., 2007; Yoshimura et al., 2007). Cilium formation was 
also found to be dependent on the Rab8 specific GAP XM_037557 (Yoshimura et al., 2007). 
Polarized transport by Rab8 is thought to be partly mediated by reorganization of actin and 
microtubules (Ang et al., 2003; Peränen et al., 1996). Rab8 also regulates the actin based 
movement of melanosomes to the PM in MDCK cells (Chabrillat et al., 2005), as well as vesicle 
transport during neuronal outgrowth. Knock-down of Rab8 with siRNA in neurons results in 
inhibition of anterograde vesicle movement and disrupts neuronal outgrowth (Huber et al., 1995). 
In addition to Rab8, vesicle formation and transport to membrane protrusions is dependent on the 
Rab8  specific  GDP/GTP  exchange  factor  Rabin8  (Hattula  et  al.,  2002).  Rab8  was  shown  to  
mediate apical protein transport in intestinal ephitelial cells in a Rab8 -/- mouse model. In 
intestinal epithelial cells Rab8 might control both direct protein transport from the TGN to the 
apical membrane, or indirectly via the basolateral membrane. In any case, Rab8 deficiency causes 
the mislocalization of apical proteins to the lysosomes, and formation of intracellular microvillus 
inclusions, resulting in dysfunction of apical microvilli and malabsorbtion (Sato et al., 2007). 
Reduced Rab8 expression was also found in a human microvillus inclusion disease patient with 
an identical ultrastructural phenotype to the Rab8-/- mouse (Sato et al., 2007). Recently it was 
also established that mutations in the MYOB5 gene, which encodes the Rab8 interacting 
myosinVb motor protein (Roland et al., 2007), also causes microvillus inclusion disease in 
humans (Muller et al., 2008). 
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Rab8 is involved in both constitutive transport of proteins from the Golgi (Huber et al., 1993) and 
basolateral vesicle transport in Madin-Darby canine kidney (MDCK) cells (Ang et al., 2003).  In 
MDCK cells, recycling endosomes might serve as intermediates for Golgi to PM transport, and as 
a common sorting organelle for the endocytic and secretory pathways (Ang et al., 2004). The 
polarized transport of proteins to the basolateral membrane is dependent on the AP-1B clathrin 
adaptor complex, which directs clatrin-coated bud formation at the TGN, and is regulated by 
Rab8 (Ang et al., 2003). The Rho GTPase CDC42 also selectively regulates the AP-1B pathway, 
and dominant negative CDC42 causes selective missorting of AP-1B dependent cargo, indicating 
that Rab8 and CDC42 might function in the same pathway (Ang et al., 2003). In addition, cell 
morphogenesis is also altered by the Rab8 interacting, TNF?-inducable protein FIP-2 
(optineurin), linking Rab8 to huntingtin (Hattula and Peränen, 2000). Optineurin also links Rab8 
to myosin VI, which acts as a motor for actin dependent transport of vesicles deriving from the 
TGN (Au et al., 2007; Sahlender et al., 2005). Mutant huntingtin (mhtt), in turn inhibits Rab8 
mediated post-Golgi trafficking, by delocalizing the optineurin/Rab8 complex from the Golgi 
(Del Toro et al., 2009).  
 
 
 
Table 2. Proteins which have been shown to interact directly with Rab8. 
Protein Function Reference 
Rabin8 Rab8 specific GEF (Hattula et al., 2002) 
XM_037557 Rab8 specific GAP (Yoshimura et al., 2007) 
Myosin Vb Molecular motor (Roland et al., 2007) 
Rabaptin5 Regulator of endocytosis (Omori et al., 2008) 
FIP-2/optineurin Vesicle trafficking (Hattula and Peränen, 2000) 
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AIMS OF THE STUDY 
 
The aim of the first part of the study was to gain insight in to the function of the NPC1 and NPC2 
proteins. Making use of a severe form of infantile NPC1 disease the goal was to identify 
individual disease causing mutations in the NPC1 protein and to study the consequences of the 
individual mutations at the cellular level. The other key goal of the study was to establish the 
intracellular location of the NPC2 protein in normal and NPC1 fibroblasts in order to gain further 
insight into the pathophysiology of NPC disease. 
 
The aim of the second part of the study was to use the cholesterol accumulation found in NPC1 
disease as a tool to identify proteins involved in the efflux of cholesterol from the endocytic 
circuits. Proteins, primarily Rab GTPases, which reduce endosomal cholesterol accumulation in 
NPC1 cells would then be further characterized in their ability to facilitate intracellular 
cholesterol transport. 
 
The aim of the third part of the study was to characterize the potential function of Rab8 in 
cellular cholesterol efflux from primary human macrophages. Macrophage foam cells are key 
elements in the development of atherosclerotic lesions and prime targets for pharmacological 
intervention. It is therefore crucial to understand the intracellular processes leading to ABCA1-
mediated cholesterol efflux. The goal of this part of the study was therefore to investigate the role 
of Rab8 in the physiological setting of macrophage foam cell formation. 
 
 METHODS 
 
Method Publication 
Cell culture I, II, III 
SDS-PAGE, Western blot, ECL (enhanced chemiluminescence) I, II, III 
 Northern blot I 
Quantitative real-time PCR III 
Surface biotinylation I, III 
Adenovirus production and infection III 
Semliki Forest virus production and infection II 
RNA isolation I, II 
Biochemical cholesterol measurements II, III 
Biochemical cholesterol ester measurements II, III 
Direct cholesterol efflux measurements II, III 
GDI extraction of Rab proteins in vitro II 
Cell fractionation II 
Recombinant protein production and purification I 
Polyclonal antibody production I 
Immunocytochemistry I, II, III 
Immunohistochemistry III 
RNA interference  II, III 
Transient transfection I, II, III 
Electroporation III 
 
 
 RESULTS AND DISCUSSION 
 
1. Defective intracellular trafficking of NPC proteins in NPC disease (I) 
 
1.1 Effects of individual mutations on the NPC1 protein  
 
Since the discovery of the two separate complementation groups in NPC it has been speculated 
that the two NPC proteins act along the same pathway and might even interact. In order to assess 
this, we sought to determine the subcellular localization of both NPC proteins, and analyze the 
effects of disease causing mutations in NPC1 on the distribution of the NPC2 protein. We 
identified three mutations, two of which were causative of NPC disease, C113R and a c-terminal 
deletion mutant (delC), and a benign polymorphism P237S. Interestingly, the P237S substitution 
has previously been regarded as a disease causing mutation (Kaminski et al., 2002). The P237S 
substitution was present in ~5% of the alleles in the Finnish and Swedish population samples 
studied. If P237S were to be a disease causing mutation one would expect the incidence of NPC1 
disease to be much higher in the Finnish and Swedish populations. Moreover, overexpression of 
the NPC1 protein harboring the P237S substitution fully restored cholesterol trafficking at the 
cellular level. Although our results rule out P237S as a disease causing mutation it is still possible 
that the mutation has a more subtle phenotype not leading to NPC1 disease.  
 
In the case of the C-terminal deletion the case is clear-cut, since it leads to an unstable protein 
which is rapidly degraded. The C113R substitution, however, results in a non-functional protein 
that is partially mistargeted. We found the C113R protein to localize mainly to the ER, Rab7-
negative endosomes and the plasma membrane. Retarded export from the ER was confirmed by 
metabolic labeling of the newly synthesized protein with 35S-methionine followed by 
immunoprecipitation and endoglycosidaseH (endoH) digestion. The C113R protein showed a 
decrease in the EndoH resistant fraction indicating that a smaller fraction of NPC1-C113R 
reached the Golgi compared to the WT protein. What might be the mechanism for the decreased 
export of NPC1-C113R from the ER? The C113R substitution resides in a highly conserved 
region of the 240 amino acid (aa) luminal N-terminus containing 13 cysteine residues. Amino 
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acids 55 through 165 encompass the “NPC” domain, a 112 aa stretch with high conservation 
between NPC1 orthologues (Watari et al., 1999a). There are 8 conserved cysteine residues within 
this domain, and site directed mutagenesis of four of these cysteines resulted in an inactive 
protein that was localized to the limiting membrane of cholesterol-laden lysosomes in NPC cells 
(Watari et al., 1999a). Presumably, the cysteine at aa position 113 participates in disulfide bridge 
formation contributing to the tertiary structure of the N-terminal domain. This region was 
recently shown to mediate oligomerisation of the NPC1 protein as well as to bind to cholesterol 
and 25-hydroxycholesterol (Infante et al., 2008a). Interestingly the stochiometry of sterol binding 
indicates that one cholesterol or hydroxycholesterol molecule binds to one dimer of the NPC1 
protein. Whether or not dimerization or oligomerization of the NPC1 protein is a requirement for 
sterol binding has not been assessed. However, it does not seem that sterols are required for the 
dimerization of the protein since an N-terminal mutant defective in sterol binding (NPC1-Q79A) 
showed the same pattern of oligomerisation as the WT protein (Infante et al., 2008a) (Linder and 
Ikonen, unpublished observations). Also the NPC1-C113R protein forms oligomers indicating the 
presumable changes in the n-terminal conformation are not sufficient to inhibit oligomerisation of 
the protein (Linder and Ikonen, unpublished observations).  
 
Although the C113R mutation clearly causes a defect in maturation of the protein it is curious 
that the protein is also mistargeted after leaving the Golgi. The putative dileucine endosomal 
targeting motif resides in the C-terminal of the protein, and ablation of this motif causes the 
retention and degradation of the protein in the ER (Watari et al., 1999a). One explanation could 
be that the C113R substitution interferes with binding to accessory proteins required for the 
proper targeting of the protein. Alternatively, sterol binding at the N-terminal is required for the 
proper localization and function of the protein. As stated above, the Q79A mutation causes a 
defect in sterol binding, whereby 25-HC binding is abolished but residual cholesterol binding 
capacity is retained. As for the C113R substitution, the cholesterol binding capacity has not been 
assessed.  
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1.2 Intracellular localization and regulation of the NPC2 protein in NPC1 cells 
 
Characterization of the NPC2 protein has been hampered by the lack of high quality commercial 
antibodies against NPC2. We generated polyclonal antibodies using recombinantly expressed 
NPC2 fused to GST (amino acids 20-151, full length NPC2 w/o signal sequence) as an epitope. 
The specificity of the antibody was confirmed by preincubation of the antibody with purified 
recombinant protein prior to IF staining. Also the specificity has been confirmed by Western blot 
using mouse NPC2 -/- samples (Mutka et al., 2004).  In normal human fibroblasts we found the 
endogenous NPC2 to have a punctate staining pattern. Double immunofluorescence staining 
indicated that the majority of NPC2 was present in Lamp1-positive lysosomes. On the other 
hand, in some cells, NPC2 was predominantly colocalized with gamma-adaptin, a marker for the 
trans-Golgi network (TGN). Taken together, these results reconcile well with MPR regulated 
shuttling of the NPC2 protein between the Golgi and endo/lysosomes. In contrast, NPC1 cells 
showed an exclusively lysosomal localization of the NPC2 protein, indicating that there is a 
sequesteration of the NPC2 protein in lysosomes. Consistent with this we saw a roughly 1.5-fold 
increase in NPC2 protein by Western blotting. This might be a result of decreased degradation of 
NPC2 or a compensatory upregulation of NPC2 gene transcription. Northern blot analysis 
showed that the NPC2 transcript was significantly upregulated indicating that the increase in 
NPC2 protein levels is due to a regulatory increase in NPC2 synthesis.  
 
In the NPC1 fibroblasts the NPC2 protein was sequestered in the cholesterol-laden lysosomes 
and  very  little  Golgi  like  staining  could  be  seen.  In  accordance  with  this  there  was  also  an  
apparent redistribution of MPR to Lamp-1 positive organelles from the normally predominant 
TGN localization. Transport of MPRs from late endosomes to the trans-Golgi is mediated by 
Rab9 (Lombardi et al., 1993; Riederer et al., 1994) and the Rab9 effector TIP47 (Carroll et al., 
2001; Diaz and Pfeffer, 1998). Interestingly Rab9 function is perturbed in NPC1 fibroblasts 
resulting in the accumulation of inactive Rab9 in late endosomes and lysosomal missorting and 
degradation of MPR (Ganley and Pfeffer, 2006). It is therefore possible that NPC2 accumulates 
as a result of defective Rab9 mediated transport steps. Whether or not this would have relevance 
for the disease phenotype is unclear, since the putative site of NPC2 function is in the 
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endo/lysosomal system, where NPC2 was shown to accumulate. In light of the increased NPC2 
mRNA levels in NPC1 fibroblasts it would seem more likely that NPC2 is upregulated by a 
compensatory mechanism as a result of the endosomal cholesterol accumulation. Alternatively, 
transcription of NPC2 might fail to be downregulated due to the relative sterol deficiency in the 
ER. It is therefore possible that the NPC proteins are transcriptionally regulated in concert to 
maintain cholesterol efflux from the endo/lysosomal compartments, but an increase in one is not 
sufficient to compensate for the loss of the other.       
 
2.   Complementation of Niemann-Pick type C disease by Rab overexpression (II) 
 
Due to the diverse cellular pathology and the abundance of metabolites that accumulate in NPC 
disease, it seems safe to argue that NPC is to a large extent a disorder of perturbed intracellular 
membrane trafficking. Whatever the functions of the NPC proteins are and the nature of the 
primary substrates, there is a gross stagnation of endosomal motility in NPC disease (Ko et al., 
2001; Zhang et al., 2001a). As of yet it has been difficult to pinpoint the exact nature of the 
cellular lesion. It seems likely that the NPC2 protein is a bona fide cholesterol transporter, 
arguing that in NPC2 disease cholesterol accumulation causes a malfunction in the endosomal 
compartments. The case for NPC1 is less clear-cut. NPC1 has been proposed to function as a 
transmembrane pump or transporter of yet unidentified substrates (Davies et al., 2000a), or as a 
cholesterol transporter in tandem with NPC2 (Infante et al., 2008b).  
 
Inactivation of the NPC1 proteins leads to the stagnation of late endosomal tubulovesicular 
trafficking (Ko et al., 2001; Zhang et al., 2001a). This phenotype might be a result of impaired 
function in select Rab GTPases, possibly through altered biophysical properties of the 
membranes. Global inactivation of Rab GTPases with Rab-GDI causes retarded endosomal 
cholesterol clearance in cultured human skin fibroblasts loaded with LDL (Höltta-Vuori et al., 
2000). Rab inhibition also disrupts complementation of NPC1 fibroblasts with overexpressed 
NPC1 protein, indicating that this process is dependent on Rab proteins (Höltta-Vuori et al., 
2000). It was subsequently shown that overexpression of the late endosomal Rabs Rab7 and Rab9 
was also able to complement the NPC1 phenotype. Of the recycling Rabs, only Rab4 has 
previously been shown to complement the NPC1 phenotype whereas Rab11 does not. We 
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therefore reasoned that overexpression of Rab proteins in NPC fibroblasts would be suitable for 
identifying novel pathways of cholesterol transport from the endosomal system. 
 
2.1 Use of filipin staining as a measure of cholesterol efflux from endosomal compartments  
 
The fluorescent antibiotic filipin has been used extensively to visualize free cholesterol in fixed 
cells. Previous complementation studies on NPC cells have used filipin staining as a measure of 
cholesterol clearance from cells. In the study we used two NPC1 cell lines and one control cell 
line. The GM3123 (I1061T/P237S) cell line from ATCC has been used extensively by other 
laboratiories for complementation and was therefore chosen. The F92-116 NPC1 and F92-99 
control cell line have been previously characterized in (I). It was immediately apparent by filipin 
staining that the cholesterol accumulation phenotype varies heavily between the GM3123 and 
F92-116 cell lines, with much more prominent perinuclear accumulation in the F92-116 line. The 
heterogeneity of filipin staining in the GM3123 line was also striking. This is noteworthy since 
previous complementation studies using single cell analysis have utilized this cell line. 
 
We initially determined if filipin could be used as a quantitative measure of cholesterol clearance 
from endosomes in NPC cells. Since the stochiometry of filipin binding to cholesterol has not 
been determined we measured the correlation between filipin intensity and cellular free 
cholesterol amounts. We found that there is good correlation between cellular free cholesterol 
amounts and filipin intensity, establishing that a decrease in filipin intensity should be a good 
measure of complementation. Indeed overexpression of Rab4-GFP and Rab7-GFP, which have 
been previously shown to complement the NPC phenotype, as well as Rab8-GFP decreased 
whole cell filipin staining. Whole cell filipin intensity can only be used as a measure of loss of 
free cholesterol i.e. through efflux or esterification, not for redistribution of free cholesterol 
within the cell. Also, a decrease in whole cell filipin staining might also reflect cholesterol efflux 
from other compartments than endosomes, e.g. the plasma membrane. Whole cell filipin intensity 
is therefore not an optimal measure of moblilization of free cholesterol from the endosomal 
system. To more precisely measure mobilization of free cholesterol from the storage 
endo/lysosomes we stained the cells with anti-Lamp1 antibodies and used this as a marker for the 
storage organelles. After image acquisition, the area under the Lamp1 positive organelles was 
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determined by image analysis and scored for filipin intensity, after subtraction of the PM filipin 
fluorescence. By specifically scoring the endosomal cholesterol content the difference between 
control F92-99 and NPC GM3123 fibroblasts becomes more apparent. Using this setup we 
showed that overexpression of GFP-tagged Rab4, Rab7, and Rab8 specifically reduced the 
cholesterol content of endosomes in NPC cells. 
 
2.2 Rab8 restores sphingolipid trafficking in NPC fibroblasts 
 
Previous studies have established the restoration of glycosphingolipid transport in parallel with 
filipin clearance during Rab overexpression (Choudhury et al., 2002; Choudhury et al., 2004). To 
test whether Rab8 also restored glycosphingolipid trafficking in NPC cells we studied the 
distribution of the cholera toxin subunit B (CTxB). CTxB binds to GM1 ganglioside and is 
normally transported to the Golgi upon internalization but is retained in the endocytic 
compartment in NPC cells (Choudhury et al., 2002; Sugimoto et al., 2001). Fluorescently labeled 
CTxB localized to punctuate cytosolic structures in GM3123 fibroblasts but in Rab8-GFP 
overexpressing cells CTxB colocalized with the Golgi marker GM130, indicating that Rab8 
restored proper glycosphingolipid trafficking in NPC1 cells.  
 
 
2.3 Rab8 is resistant to membrane retention during cholesterol loading  
 
Membrane cholesterol loading, as seen in NPC disease, disrupts Rab function by interfering with 
Rab membrane extraction by Rab-GDI (Choudhury et al., 2004; Ganley and Pfeffer, 2006; 
Lebrand et al., 2002). In NPC cells, and upon acLDL loading of mouse peritoneal macrophages, 
we observed an upregulation of the Rab8 protein. To investigate whether this increase in Rab8 
was caused by sequestration of Rab8 in cholesterol enriched membranes, we incubated cellular 
membranes with Rab-GDI. Incubation with 2µM purified GDI solubilized roughly 70% of 
membrane bound Rab8 independent of cholesterol load. In contrast, Rab7 solubility was reduced 
in NPC cells in accordance with previous reports (Lebrand et al., 2002). Apparently the 
membranes that Rab8 resides in do not accumulate cholesterol in NPC cells, and therefore the 
membrane extractability remains unaltered.  Interestingly, the overall membrane extractability of 
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Rab8 seemed to be greater for Rab8 compared to Rab7. Rab8 is only geranylgeranylated at a 
single site as opposed to the double prenylation of most other Rab proteins e.g. Rab7, which 
might confer resistance to membrane sequestration during cholesterol loading. Also, the affinity 
for Rab-GDI depends on the length of the hypervariable domain of the Rab protein. The high 
membrane extractability of Rab8 might therefore help Rab8 to stay functional during cholesterol 
enrichment of membranes.     
 
2.4 Rab8 siRNA induces a cholesterol accumulation phenotype  
 
So far only global inactivation of Rab proteins with Rab-GDI has been shown to induce a 
cholesterol storage phenotype, whereas RNAi of specific Rabs has been ineffective. Ganley and 
coworkers showed that specific knock-down of Rab9 did not induce endosomal cholesterol 
accumulation (Ganley and Pfeffer, 2006). It is therefore possible that overexpression of certain 
Rab proteins stimulates cholesterol transport in redundant or marginal pathways. To evaluate if 
Rab8 function is necessary for cholesterol trafficking in normal cells we knocked down the Rab8 
protein using RNA interference. Transfection of primary human fibroblasts with Rab8 shRNA 
resulted in an increase in intracellular cholesterol, as assessed by filipin staining, that partly 
localized to Lamp1 positive organelles. The cholesterol accumulation was also accompanied by a 
cholesterol efflux defect to apoA-I. Also, Rab8 RNAi resulted in decreased cholesterol 
esterification, indicating that the mobilized cholesterol was not targeted to the ER. 
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3. Rab8 regulates cholesterol processing in primary human macrophages (III) 
 
3.1 Rab8 is expressed in macrophages present in atherosclerotic lesions in vivo 
 
To assess if Rab8 might be beneficial in foam cell reduction we opted to work on primary human 
macrophages. Initially, we conducted immunohistochemical staining of human coronary artery 
sections of atherosclerotic lesions. Using a polyclonal antibody against Rab8 we found Rab8 to 
be expressed in cells surrounding the necrotic core of the lesion. To confirm that these cells were 
macrophages we double stained the sections with anti-Rab8 and anti-CD68 antibodies. The Rab8 
expressing cells showed clear co-localization with CD68 indicating that the cells were indeed 
macrophages. The results indicate that Rab8 might have a physiological role in the setting of 
macrophage foam cell formation, but whether this is directly related to cholesterol metabolism 
can not be determined from these experiments. 
 
3.2 Adenoviral overexpression of Rab8 in vitro increases ABCA1 dependent cholesterol 
efflux to apoA-I 
 
We used an adenoviral expression system to overexpress Rab8 in primary human macrophages. 
Infection of macrophages with Rab8 induced marked morphological changes, as has previously 
been shown in other cell types. The macrophages displayed multiple cell protrusions positive for 
Rab8. To assess if these cells also showed an increased capacity to withstand foam cell formation 
we incubated control (GFP) or Rab8-myc infected macrophages in the presence of acLDL and 
apoA-I. Cells infected with Rab8 accumulated less total cholesterol as compared to the control 
cells. Interestingly this decrease in total cholesterol could be accounted for by the total decrease 
in cholesteryl esters indicating that the cholesteryl ester pool is mainly affected. This could be 
due rapid recycling of cholesterol from the endosomes to the cell surface, thereby decreasing the 
cholesterol pool that is available for re-esterification in the ER. Alternatively, Rab8 might 
facilitate the mobilization of cholesterol from lipid droplets. Since the amount of free cholesterol 
remained constant during Rab8 overexpression it would seem that the mobilized cholesterol is 
readily effluxed from the cells, suggesting involvement of the ABCA1 transporter. In accordance 
with this we saw a striking, 2.5-fold increase in the amount of ABCA protein in the Rab8 
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overexpressing cells. This increase of ABCA1 was unlikely to be caused by an increase in 
ABCA1 transcription through e.g. LXR activation since we saw no significant upregulation of 
the ABCA1 mRNA in quantitative real-time PCR. It is therefore logical to assume that Rab8 
induces the stabilization of ABCA1 on the cell surface, and thereby retards the degradation of the 
protein. Stabilization might occur through increased exposition of ABCA1 to extracellular apoA-
I through enhanced trafficking of ABCA1 to the PM. It has previously been shown that 
degradation of ABCA1 is regulated by internalization of the protein, and that apoA-I decreases 
internalization by stabilizing ABCA1 at the cell surface (Wang et al., 2003). Internalization of 
ABCA1 is dependent on the C-terminal PEST sequence (Chen et al., 2005). Given the 
established effects of Rab8 on actin remodelling it is also feasible that ABCA1 stabilization is an 
actin-mediated effect. ABCA1 has been shown to interact with members of the syntrophin family 
of proteins (?1, ?1 and ?2) (Buechler et al., 2002; Munehira et al., 2004; Okuhira et al., 2005). 
Overexpression of ?1- syntrophin increases the half-life of ABCA1 and facilitates cholesterol 
efflux (Munehira et al., 2004). Co-expression of ?1-syntrophin and ABCA1 induces the 
formation of ABCA1 clusters at the PM, stabilizing the ABCA1 protein and increasing efflux 
capacity (Okuhira et al., 2005). The syntrophins link ABCA1 to the actin cytoskeleton by 
forming a complex with the scaffolding protein utrophin. Rab8 might therefore facilitate 
cholesterol efflux by providing the actin scaffold for stabilization of the 
ABCA1/syntrophin/utrophin complex.  
 
 
3.3 Rab8 RNAi inhibits cholesterol efflux and regulates ABCA1 trafficking in primary 
human macrophages 
 
To establish if Rab8 is essential for cholesterol transport in primary human macrophages we used 
RNA silencing to knock down the Rab8 protein. We previously showed that Rab8 siRNA in 
primary human macrophages causes retention of cholesterol within the cells as assessed by filipin 
staining (II). In the primary human macrophages we opted to biochemically assess the cholesterol 
amounts in Rab8 knock-down and control cells. Two days after electroporation of the siRNA the 
macrophages were loaded with 50 ?g/ml acLDL. This resulted in a marked, 3-fold increase in 
total cellular cholesterol and an increase of the cholesteryl ester fraction from ?3.5% to ?45%. 
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After acLDL loading the cells were incubated with 10 ?g/ml apoA-I for 18h. In control cells, the 
total cellular cholesterol levels decreased by 40% during the incubation period, whereas the Rab8 
depleted cells failed to efflux significant amounts of cholesterol. To confirm that the substrate 
pool for efflux was derived from the endocytosed lipoprotein particles we labeled acLDL with 
?3H?cholesteryl oleate. Scintillation counting of the cells after loading confirmed equal uptake of 
the label. However after incubation with apoA-I, the Rab8 depleted cells failed to efflux the 
?3H?cholesterol, in accordance with the previous results. 
 
After endocytosis the cholesteroyl esters of the LDL particle are hydrolysed by lysosomal acid 
lipase (LAL), and it is conceivable that Rab8 siRNA interferes with this step and therefore 
inhibits cholesterol mobilization from the cells. This is, however, an unlikely scenario since Rab8 
shRNA causes cholesterol accumulation in primary human fibroblasts as assessed by filipin 
staining, and filipin only stains free cholesterol. There are a number of possibilities how Rab8 
siRNA might interfere with cholesterol efflux. Firstly, Rab8 depletion might inhibit the 
trafficking of recycling endosomes to the cell surface. In accordance, filipin staining of primary 
human macrophages showed cholesterol accumulation in both Lamp1-positive and Lamp1-
negative organelles. This accumulation is separate from that seen in NPC1 disease, which is 
primarily lysosomal in nature, indicating that Rab8 regulates a down-stream event in cholesterol 
trafficking. As discussed above, one possibility is that Rab8 controls the stabilization of ABCA1 
on the PM. To assess the effect of Rab8 on the plasma membrane localization of ABCA1 we 
used RNA silencing to knock down Rab8, followed by surface biotinylation of ABCA1. In Rab8 
siRNA treated cells there was a significant, 30% decrease in the fraction of ABCA1 on the 
plasma membrane, indicating that Rab8 regulates the transport of ABCA1 to the PM or 
stabilization of the protein on the PM.  
 
It is possible that Rab8 controls the trafficking or recycling of ABCA1 to the cell surface. Due to 
a lack of good antibodies the precise cellular localization of ABCA1 has been hard to pinpoint, 
although it is clear through surface biotinylation experiments that a large portion of the protein 
resides at the plasma membrane. By overexpressing GFP-tagged ABCA1 it has also been 
suggested that ABCA1 resides in endosomal compartments. It seems that a part of this pool of 
ABCA1 is destined for lysosomal degradation, whereas a part is recycled back to the PM 
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(Neufeld et al., 2001). Yet, the specific recycling route has not been identified. Since Rab8 
affects the cell surface distribution of ABCA1 we studied whether Rab8 siRNA would also have 
an effect on the intracellular distribution of ABCA1-GFP. Previous studies on ABCA1-GFP have 
mostly been carried out in HeLa cells. In a study by Neufeld et al, ABCA-GFP was localized to 
the plasma membrane and Lamp2-positive vesicles, but not to TfR-positive vesicles (Neufeld et 
al., 2001). We also found ABCA1-GFP to localize to the PM in HeLa cells, mainly to cellular 
lamellipodia like protrusions and to intracellular tubules, both colocalizing with ?1 integrin. Rab8 
siRNA caused a decrease in cellular protrusions in the ABCA1 expressing cells and retention of 
ABCA1 and ?1 integrin in intracellular tubular compartments, indicating that the trafficking of 
b1 integrin and ABCA1-GFP are interconnected. In accordance with previous results (Neufeld et 
al., 2001) we did not find ABCA1 to colocalize with TfR. However, in Rab8 siRNA treated cells 
ABCA1 accumulated perinuclearily, in a partially TfR positive structure. Taken together, the 
results indicate that Rab8 also regulates the intracellular trafficking of ABCA1. 
 CONCLUSIONS AND FUTURE PROSPECTS 
  
In this study (I) we have identified a mutation in the NPC1 protein that disrupts the intracellular 
trafficking of the protein, leading to a severe infantile form of NPC disease. The study 
demonstrates the importance of the correct localization of NPC1 within the cell. Also, the 
regulation of NPC2 gene transcription seems to be dependent on proper NPC1 function 
indicating that these proteins might be functionally linked. Of the various domains in the NPC1 
protein, the SSD is of outstanding interest. There is high sequence homology within this domain 
between SCAP, HMGR, NPC1L1 and NPC1 (Kuwabara and Labouesse, 2002). Therefore, a 
crucial challenge will be to establish whether the SSD performs a similar sterol-sensing function 
in NPC1 as has been described for SCAP and HMGR, and if so, to establish the sterols that 
regulate NPC1 function.  
 
The lessons learned from NPC1 might also have impact on our understanding of the regulation of 
other SSD containing proteins, e.g. NPC1L1. Conversely, mutational and functional analysis of 
the SSD within NPC1L1 might shed light on the function of this domain within NPC1. It has 
already been established that sterols regulate the intracellular trafficking of NPC1L1. Upon sterol 
depletion NPC1L1 translocates from the endocytic recycling compartment to the plasma 
membrane where it facilitates cholesterol uptake. It would be interesting to study whether the 
trafficking of NPC1L1 is dependent on an intact SSD. A recent study also showed that 
cholesterol induces the internalization of NPC1L1 in intestinal cells, and that the cholesterol 
lowering drug ezetimibe blocks this internalization (Ge et al., 2008). It would therefore be of 
interest to determine if ezetimibe added to cells in vitro could block NPC1 mediated 
tubulovesicular trafficking. If so, this could suggest that the function of NPC1 could be the 
generation of vesicle budding sites as proposed by Yiannis Ioannou (Ioannou, 2005). In this 
model NPC1 would function by flipping membrane lipids such as fatty acids or sphingosine, 
thereby facilitating an outward bending membrane curvature. However, any theory on the 
function of NPC1 should also take in to account the cholesterol binding properties of the protein. 
In analogy to NPC1L1 internalization, cholesterol might also serve as an activating trigger for 
NPC1 function. A regulatory role for cholestrerol binding could explain why an NPC1 N-
terminal mutant with lack of 25-hydroxycholesterol binding and severely attenuated cholesterol 
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binding had no apparent cellular phenotype (Infante et al., 2008a). It is feasible that the residual 
cholesterol binding capacity is sufficient to serve a regulatory function. The bulk cholesterol 
transport would then be mediated by NPC2 to specific membrane domains created by NPC1. 
NPC2 is capable of transferring cholesterol from the N-terminal domain of NPC1 to acceptor 
membranes (Infante et al., 2008b). It is also possible that NPC2 could work in the opposite way, 
transferring cholesterol from inner membranes to NPC1 at the limiting membrane. In this model 
cholesterol transfer from inner membranes could be facilitated by LBPA/BMP, which has been 
shown to increase the sterol transfer capacity of NPC2 when present in the donor membrane 
(Cheruku et al., 2006). 
 
To date, most studies aimed at elucidating the function of NPC1 have focused on transient 
transfection to revert the accumulation phenotype. An alternative approach could be the acute 
knock-down of NPC1 or NPC2, to assess which metabolite(s) accumulate first. This might help 
to resolve the long standing hen-and-egg issue that has puzzled NPC researchers, i.e. which 
comes first, cholesterol or sphingolipid accumulation. However, such a study should also take in 
to account the sterol status of the cell, as well as the inherent difference in the sensitivities 
between assays for cholesterol and sphingolipid accumulation.   
     
Our studies (II, III) are the first to identify a specific Rab-GTPase localized outside the 
endosomal system that affects the recycling of cholesterol from the endosomes to the PM. We 
have also shown that Rab8 is involved in the cellular trafficking of ABCA1. It is clear that the 
processes governing ABCA1-mediated cholesterol efflux to apoA-I are highly complex, 
involving intracellular signaling cascades and cytoskeleton reorganization. Given the role of 
Rab8 in inducing cell polarity and actin as well as microtubule reorganization, a likely scenario is 
that Rab8 promotes cholesterol efflux by creating platforms for cholesterol efflux at the leading 
edge of the cell. Although the contribution of endocytosed ABCA1/apoA-1 to cellular cholesterol 
efflux remains to be resolved, it is quite clear that ABCA1 is regulated post-transcriptionally 
through endocytosis and recycling of the protein. According to our results Rab8 has a role in this 
process, but the precise mechanism of Rab8 function remains to be established. We have shown 
that knock-down of Rab8 causes the retention of ABCA1 within the cell in ?1 integrin and TfR 
receptor positive structures. It remains to be established whether ABCA1 containing vesicles 
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utilize Rab8 directly, e.g. for recruitment of myosin motors, or if the effect is secondary e.g. 
through altered actin or microtubule organization.  
 
Our results also suggest that Rab8 recycles cholesterol from the endosomal system back to the 
plasma membrane. The next challenge will therefore be to identify the precise recycling 
pathway(s) regulated by Rab8 other Rab proteins involved in this process. The strategy adopted 
in this study i.e. transfection of select Rab proteins and single cell assessment of filipin intensity 
is quite labor intensive. In order to identify the Rab proteins involved in intracellular cholesterol 
trafficking there is therefore a need for high throughput approaches, for instance, utilization of 
siRNA libraries with automated analysis. Alternatively, a Rab-GAP library such as the one used 
to identify Rab-GTPases involved in primary cilium formation could be used (Yoshimura et al., 
2007). The challenge of these approaches is, however, to find a clear read-out for cholesterol 
trafficking suitable for automated analysis, preferably in living cells. The filipin staining process 
is not suitable for high throughput applications. To this end one might utilize fluorescent 
cholesterol analogs to measure changes in uptake, intracellular distribution and efflux. One 
candidate probe would be BODIPY-cholesterol which has been shown to behave similarly to 
cholesterol in normal and storage-disease cells (Höltta-Vuori et al., 2008). 
 
Finally, it would be interesting to carry out in vivo studies in mice. The Rab8-/- mice described 
by Sato and colleagues could be used for such studies, for instance to assess the serum 
lipoprotein particle composition during low and high cholesterol diet (Sato et al., 2007). 
Alternatively, generation of transgenic mice between Rab8-/- and LDLr-/- (or apoE-/-) mice 
might be used to assess the effect of Rab8 deficiency on atherosclerotic plaque development. 
Also, bone marrow transplants from Rab8 KO mice to LDLr -/- mice might be used to directly 
assess the contribution of Rab8 in foam cell development. 
 
Macrophage RCT measurements in vivo could also be carried out by adenoviral infection of 
macrophages with Rab8, and metabolic labeling with [3H]-cholesterol in vitro, followed by 
intraperitoneal injection of infected macrophages. RCT could then be measured by the 
appearance of the [3H]-tracer in the plasma, liver and feces (Tanigawa et al., 2007). Together 
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these approaches should determine the overall contribution of Rab8 in macrophage RCT and 
atherosclerotic lesion development.  
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